Skip to main content

Medicine's Nathan Berger and Rong Xu shares research suggesting how popular diabetes and weight loss drugs could reduce risk of colorectal cancer

MEDIA | January 25, 2024
STORY BY: EDITORIAL STAFF

Popular diabetes, weight loss drugs could reduce risk of colorectal cancer

Crain’s Cleveland Business (subscription required): Nathan Berger, the Hanna-Payne Professor of Experimental Medicine, and Rong Xu, professor at the School of Medicine, discussed their new research finding that a class of medications used to treat Type 2 diabetes and weight loss—under which the newly popular Ozempic and Wegovy are categorized—could reduce the risk of colorectal cancer.